Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 2/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | YES1 | P07947 | 1/20 | 0.31 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.31 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.31 |
| ▸ | LTK | P29376 | 1/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | MST1R | Q04912 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL534854 | 1.00 | MET (0.33) | METALDH1A1F2GLAHPGD | |
| SCHEMBL535447 | 0.90 | ALDH1A1 (0.34) | METALDH1A1F2GLAHPGD | |
| SCHEMBL535446 | 0.90 | ALDH1A1 (0.34) | METALDH1A1F2GLAHPGD | |
| SCHEMBL534510 | 0.89 | MET (0.34) | METALDH1A1F2GLAHPGD | |
| SCHEMBL534509 | 0.89 | MET (0.34) | METALDH1A1F2GLAHPGD | |
| SCHEMBL535522 | 0.89 | SCN9A (0.35) | METALDH1A1KDM4EKMT2ASCN9A | |
| SCHEMBL535521 | 0.89 | SCN9A (0.35) | METALDH1A1KDM4EKMT2ASCN9A | |
| SCHEMBL534819 | 0.89 | MET (0.35) | METALDH1A1F2GLAHPGD | |
| SCHEMBL534820 | 0.89 | MET (0.35) | METALDH1A1F2GLAHPGD | |
| SCHEMBL535328 | 0.88 | ALDH1A1 (0.33) | METALDH1A1F2GLAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507509-B2 | Saturated and insaturated bi- or tricyclic aryloxyacetamine derivatives and their use as fungicides | SYNGENTA CROP PROTECTION LLC (US) | 2013-08-13 | — | — | US | disclosed |
| EP-2185518-B1 | Aryloxyacetamide derivatives and their use as fungicides | SYNGENTA PARTICIPATIONS AG (CH) | 2012-02-08 | — | — | EP | disclosed |
| US-20100298356-A1 | SATURATED AND INSATURATED BI- OR TRICYCLIC ARYLOXYACETAMINE DERIVATIVES AND THEIR USE AS FUNGICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| EP-2185518-A2 | SATURATED AND INSATURATED BI- OR TRICYCLIC ARYLOXYACETAMIDE DERIVATIVES AND THEIR USE AS FUNGICIDES | Syngenta Participations AG (CH) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009030467-A2 | SATURATED AND INSATURATED BI- OR TRICYCLIC ARYLOXYACETAMIDE DERIVATIVES AND THEIR USE AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG, (CH) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298356-A1 | SATURATED AND INSATURATED BI- OR TRICYCLIC ARYLOXYACETAMINE DERIVATIVES AND THEIR USE AS FUNGICIDES | CYP1A2, CYP1B1, CYP1A1 | MET 780/4885ALDH1A1 109/4885F2 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.